Get started
Avidity Biosciences, Inc.Avidity Biosciences, Inc.Avidity Biosciences, Inc.

Avidity Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RNA chart


Full chart

RNA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.77 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.90 USD
Net income (FY)
‪−212.22 M‬ USD
Revenue (FY)
‪9.56 M‬ USD
Shares float
‪108.55 M‬
Beta (1Y)
2.09

Employees


Employees (FY)
253
Change (1Y)
+67 +36.02%
Revenue / Employee (1Y)
‪37.79 K‬ USD
Net income / Employee (1Y)
‪−838.81 K‬ USD

About Avidity Biosciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Sarah Boyce
Website
aviditybiosciences.com
Headquarters
San Diego
Founded
2012
FIGI
BBG00FQ7LXW1
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RNA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RNA is 31.35 USD — it has decreased by −0.92% in the past 24 hours. Watch Avidity Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Avidity Biosciences, Inc. stocks are traded under the ticker RNA.
RNA stock has fallen by −3.69% compared to the previous week, the month change is a −26.34% fall, over the last year Avidity Biosciences, Inc. has showed a 240.39% increase.
We've gathered analysts' opinions on Avidity Biosciences, Inc. future price: according to them, RNA price has a max estimate of 96.00 USD and a min estimate of 51.00 USD. Watch RNA chart and read a more detailed Avidity Biosciences, Inc. stock forecast: see what analysts think of Avidity Biosciences, Inc. and suggest that you do with its stocks.
RNA reached its all-time high on Nov 13, 2024 with the price of 56.00 USD, and its all-time low was 4.83 USD and was reached on Oct 31, 2023. View more price dynamics on RNA chart.
See other stocks reaching their highest and lowest prices.
RNA stock is 2.24% volatile and has beta coefficient of 2.09. Track Avidity Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Avidity Biosciences, Inc. there?
Today Avidity Biosciences, Inc. has the market capitalization of ‪3.74 B‬, it has decreased by −3.36% over the last week.
Yes, you can track Avidity Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Avidity Biosciences, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
RNA earnings for the last quarter are −0.65 USD per share, whereas the estimation was −0.71 USD resulting in a 8.63% surprise. The estimated earnings for the next quarter are −0.79 USD per share. See more details about Avidity Biosciences, Inc. earnings.
Avidity Biosciences, Inc. revenue for the last quarter amounts to ‪2.34 M‬ USD, despite the estimated figure of ‪4.07 M‬ USD. In the next quarter, revenue is expected to reach ‪1.63 M‬ USD.
RNA net income for the last quarter is ‪−80.40 M‬ USD, while the quarter before that showed ‪−70.79 M‬ USD of net income which accounts for −13.57% change. Track more Avidity Biosciences, Inc. financial stats to get the full picture.
No, RNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 253.00 employees. See our rating of the largest employees — is Avidity Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Avidity Biosciences, Inc. EBITDA is ‪−322.04 M‬ USD, and current EBITDA margin is ‪−2.44 K‬%. See more stats in Avidity Biosciences, Inc. financial statements.
Like other stocks, RNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Avidity Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Avidity Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Avidity Biosciences, Inc. stock shows the buy signal. See more of Avidity Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.